An In-Depth Review of Interstitial Lung Diseases: Epidemiology, Pathogenesis, and Clinical Management
OthersPage Navigation
Introduction
Interstitial lung diseases (ILDs) represent a heterogeneous group of disorders characterized by various forms of interstitial lung pathology. This article provides an in-depth review of the epidemiology, pathogenesis, and clinical management of ILDs.
Epidemiology
ILDs are relatively rare, with an estimated prevalence of 30-50 cases per 100,000 individuals. The incidence increases with age, particularly among those above 60 years. Certain occupations and environmental exposures, such as mining, farming, and bird handling, are associated with a higher risk of developing ILDs.
Pathogenesis
The pathogenesis of ILDs is complex and multifactorial, often involving a combination of genetic predisposition, environmental exposures, and immune dysregulation. The common pathological feature is the accumulation of inflammatory and fibrotic cells in the interstitial spaces, leading to progressive scarring and architectural distortion of the lung parenchyma.
Clinical Management
The management of ILDs is challenging due to their progressive nature and lack of curative treatments. The mainstay of therapy is immunosuppression, aimed at reducing inflammation and fibrosis. Lung transplantation remains the only definitive treatment for severe, end-stage ILDs. Recent advances in targeted therapies, such as antifibrotic drugs, have shown promise in slowing disease progression.
Conclusion
ILDs are a diverse group of disorders with complex pathogenesis and challenging management. Understanding the epidemiology and pathogenesis can aid in early detection and intervention. Further research is needed to develop more effective treatments and improve the prognosis of patients with ILDs.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Oncologist Sued for Double-Billing; Pharmacy Deserts; 'She Loved Scotch and Pizza'
2.
Renewing the call for a national Cancer Patient's Bill of Rights
3.
Woman Loses 6-Year Battle With Mouth Tumor
4.
Pressing the Sleep button could have a positive impact on cognition.
5.
FDA Approves Iberdomide Combo for Multiple Myeloma
1.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
2.
HPV and Immunotherapy in Cancer Survivorship: National Cancer Survivors Day Review
3.
Polycythemia Vera: A Historical Perspective and Contemporary Management
4.
ctDNA in Aggressive B-Cell Lymphoma: Redefining MRD and Prognostic Monitoring
5.
Prevention Through Survivorship-Focused Strategies for Preserving Functional Independence After Cancer
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
3.
The Role of Platelets in Normal Blood Clotting
4.
Comprehensive Update on Hematology
5.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge